Chemokine receives US FDA approval for phase II study of liver cancer drug Thursday, January 10, 2008 Chemokine Therapeutics Corporation received notice from the US Food and Drug Administration (FDA) allowing the company to begin a phase II study in liver cancer with its lead drug candidate, CTCE-9908. The phase II trial will be a multi-centre, randomised, controlled, open label study assessing the efficacy and safety of CTCE-9908 administered at a dose of 5 mg/kg. The primary end point will be to determine the response rate of tumours in patients with liver cancer treated with CTCE-9908 following transarterial chemoembolization (TACE) compared with patients receiving TACE alone. The Company will follow patients to also determine progression free survival, overall survival, as well as various tumour and angiogenic factors.